Leucine Rich Bio Pvt Ltd, South Asia’s first microbiome company and the force behind the BugSpeaks brand, successfully hosted the third edition of World of Microbiome 2026 at Bengaluru. The one-day flagship conference brought together clinicians, researchers, nutritionists, biotech leaders, entrepreneurs, investors and wellness professionals to advance microbiome science and its real-world applications in preventive healthcare and precision wellness.
Nitesh Agarwal, Chief Investment Officer at Baldota Family Office Fund, with over 17 years of experience in PE/VC investing and a strong focus on startups and venture capital funds across India, the US, and Israel, graced the occasion as the Guest of Honour. This event had sessions that were dedicated to health and wellness microbiota, intellectual property and clinical trials in the wellness sector, and precision nutrition and microbiome. Panel discussions revolved around the enablers for next-generation diagnostics, therapeutics and current microbiome trends outside of India. Attendees got the chance to participate in keynotes, expert presentations, networking and an audience quiz.
Speakers included Dr. Debojyoti Dhar, Co-Founder & Director, Leucine Rich Bio; Kumar Sankaran, Founder & CEO, BugSpeaks; Dr. Astha Agrawal; Dr. Yugandhar Reddy of Unilever India; Dr. Kiran Ambatipudi of IIT Roorkee; Dr. Lipika Sahoo; Dr. Mukul Maurya; Dr. Rohini Prasad of BugSpeaks; and other leading voices from clinical practice, industry and academia.
“The future of healthcare starts with comprehending our microbiome ecosystem,” Dr. Debojyoti Dhar, Co-Founder & Director of Leucine Rich Bio, stated at World of Microbiome 2026. ‘BugSpeaks 3.0 – Microbiome with a pinch of AI’ was the title of the talk given by Kumar Sankaran, Co-Founder and CEO of Leucine Rich Bio. He said, “With the advent of AI, microbiome analysis and reporting can go to the next level”
Organised by Leucine Rich Bio, the company behind BugSpeaks, South Asia’s first clinically verified gut microbiome test, the summit builds on more than a decade of experience, partnerships with over 100 clinical and 50 industry collaborators, and a growing presence across 15-plus countries. The event reaffirmed its position as South Asia’s dedicated platform for microbiome research, innovation and practical application.
